Seeking Alpha
18 Jan 2026, 09:32 UTC · 34w ago
Verdict
Headline takes no side. We score GH +1.00 across four claims — strongly bullish.
+1.00strongly bullish
More positive than 98% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Guardant Health's screening volumes have increased by 335% year-over-year driven by the Shield blood-based colorectal cancer test.
More positive than 98% of claims this week
FY2025 revenue is projected at $981 million, representing a 33% year-over-year increase.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 91% of claims this week
Guardant Health has entered a transformative collaboration with Quest Diagnostics to expand screening access to 50 million Americans.
More positive than 84% of claims this week
Preliminary Q4 revenue reached $280 million, a 39% increase year-over-year.
More positive than 76% of claims this week
Which stocks this story touches
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
24/7 Wall Street
2h ago
+61.0%
Price agrees with the score
$180.56 vs $112.14 close before publication (Jan 16) · not market-adjusted
GH chart →
